Valuation: StemRIM

Market Cap 1.87TCr 12Cr 11Cr 9.82Cr 8.95Cr 17Cr 1.14TCr 17Cr 118.85Cr 46Cr 582.02Cr 44Cr 43Cr P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 1.17TCr 7.41Cr 6.58Cr 6.14Cr 5.6Cr 11Cr 712.21Cr 11Cr 74Cr 29Cr 364.09Cr 28Cr 27Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
1 day-3.53%
1 week-6.29%
Current month-3.53%
1 month-47.60%
3 months-47.10%
6 months-46.58%
Current year-37.64%
1 week 161
Extreme 161
185
1 month 161
Extreme 161
337
Current year 161
Extreme 161
368
1 year 161
Extreme 161
368
3 years 161
Extreme 161
752
5 years 161
Extreme 161
1,518
10 years 161
Extreme 161
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 01/02/2007
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%-6.29%-43.45%-78.31% 6.52Cr
-0.61%-3.43%+39.40%+112.31% 1,01900Cr
-1.02%-5.60%+37.67%+65.02% 62TCr
+1.11%-0.58%+11.10%+77.28% 46TCr
+0.34%-3.01%+61.21%+40.71% 36TCr
-0.95%-4.05%+21.60%+39.37% 33TCr
-1.46%-2.89%+11.84%+24.60% 27TCr
-1.35%-5.43%-4.69%+8.40% 24TCr
-1.04%-2.79%+35.52%+51.34% 22TCr
-1.87%-4.10%+30.92%+95.33% 18TCr
Average -0.56%-3.68%+20.11%+43.61% 36.97TCr
Weighted average by Cap. +0.42%-3.33%+30.52%+68.95%

Financials

2024 2025
Net sales - -
Net income -202.2Cr -1.28Cr -1.14Cr -1.06Cr -96.9L -1.83Cr -123.24Cr -1.84Cr -13Cr -4.99Cr -63Cr -4.81Cr -4.71Cr -192.9Cr -1.22Cr -1.09Cr -1.01Cr -92.44L -1.74Cr -117.57Cr -1.76Cr -12Cr -4.76Cr -60Cr -4.59Cr -4.49Cr
Net Debt -841Cr -5.33Cr -4.74Cr -4.42Cr -4.03Cr -7.6Cr -512.6Cr -7.67Cr -54Cr -21Cr -262.05Cr -20Cr -20Cr -699.4Cr -4.43Cr -3.94Cr -3.68Cr -3.35Cr -6.32Cr -426.29Cr -6.38Cr -45Cr -17Cr -217.93Cr -17Cr -16Cr
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
02/26/02 JP¥164.00 -3.53% 2,52,800
01/26/01 JP¥170.00 0.00% 2,57,900
30/26/30 JP¥170.00 +2.41% 4,39,300
29/26/29 JP¥166.00 -3.49% 5,98,400
28/26/28 JP¥172.00 -1.71% 5,50,400
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock